<DOC>
	<DOCNO>NCT01538212</DOCNO>
	<brief_summary>This evaluation efficacy safety AXONA chart review carry 16 practice AXONA prescribe treatment patient mild-to-moderate AD . Efficacy AXONA assess comparison patient status initiation treatment .</brief_summary>
	<brief_title>Retrospective Cohort Study Of The Efficacy Of Axona® ( Medium Chain Triglycerides ) In Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>The primary objective ass efficacy AXONA ( medium chain triglyceride [ MCTs ] ) use alone combination agent patient mild-to-moderate Alzheimer 's disease ( AD ) routine clinical practice .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient Male female outpatient age ≥ 50 year diagnosis probable AD mildtomoderate severity MMSE score 14 24 inclusive initiation AXONA treatment ( available ) Has receive Axona duration ≥ 6 month Caregiver Inclusion Criteria ( applicable ) : Must least 21 year age , primary caregiver since prior initiation Axona , provide least 4 hour supervision direct assistance per day patient able perform assessment . Patient MMSE score &lt; 14 time AXONA treatment initiate Presence comorbid disease know adversely impact cognitive function ( e.g. , Parkinson 's disease , history cerebral infarct , dementia Lewy body ) Vascular dementia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>retrospective</keyword>
	<keyword>Axona</keyword>
</DOC>